Tin tức & Cập nhật
Xem bài viết Ung thư
Xem
Chỉ hiển thị Multimedia

Ivonescimab trumps tislelizumab for squamous NSCLC in HARMONi-6
06 Jan 2026
bởiAudrey Abella
In the phase III HARMONi-6 trial, ivonescimab plus chemotherapy significantly improved progression-free survival (PFS) compared with tislelizumab plus chemo as first-line treatment for individuals with advanced squamous non-small cell lung cancer (NSCLC).
06 Jan 2026







